DDInter583 DDInter1676
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Donepezil {u} (Compound) resembles {v} (Compound) Doxazosin
Donepezil {u} (Compound) resembles {v} (Compound) Moexipril
Donepezil {u} (Compound) treats {v} (Disease) Alzheimer's disease
Donepezil {u} (Compound) binds {v} (Gene) CYP2D6
Donepezil {u} (Compound) upregulates {v} (Gene) MAPKAPK5
Donepezil {u} (Compound) downregulates {v} (Gene) CCNB2
Donepezil {u} (Compound) causes {v} (Side Effect) Abdominal pain upper
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zafirlukast
Donepezil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Donepezil (Compound) resembles Doxazosin (Compound)
Donepezil (Compound) resembles Moexipril (Compound)
Donepezil (Compound) treats Alzheimer's disease (Disease)
Donepezil (Compound) binds CYP2D6 (Gene)
Donepezil (Compound) upregulates MAPKAPK5 (Gene)
Donepezil (Compound) downregulates CCNB2 (Gene)
Donepezil (Compound) causes Abdominal pain upper (Side Effect)
Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Donepezil may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin